Abstract:Background: Energy metabolism deficiency is part of the acute kidney injury (AKI) pathophysiology. Recent studies highlighted the role of nicotinamide adenine dinucleotide (NAD) production in the pathogenesis of AKI. NAD is an electron carrier for mitochondria and a cofactor for cytoplasmic redox reactions. Its production is decreased during AKI following a decrease of the expression of PGC1 α (Peroxisome proliferator activated receptor gamma co-activator-1-α ) and an alteration of its de novo synthesis pathway: with a reduction in the expression of the Quinolinate PhosphoRibosylTransferase (QPRT). The modulation of this de novo pathway has been studied mainly in the acute phase immediately after AKI. However, its correlation with the severity of the ischemic insult and its evolution during the transition from AKI to CKD have not been described yet. Methods: Renal ischemia-reperfusion was performed in C57Bl6/J male mice after nephrectomy of the contralateral kidney. For the ’severity’ study, a 5-30 minutes ischemia was performed. Renal function was assessed 24h after ischemia. For the ‘AKI to CKD’ study, renal ischemia was performed during 10 minutes. Mice were sacrificed 1, 2, 3, 6 and 28 days after ischemia. PGC1 α and QPRT mRNA expression was measured by RT-qPCR. Results: We induced AKI in mice by unilateral ischemia reperfusion injury of increasing time to induce several degrees of AKI severity. PGC1 α and QPRT mRNA expression decreased progressively with ischemia severity until reaching a plateau at 15 minutes of ischemia for PGC1 α , like plasma creatinine and urea, whereas QPRT decrease is linear until 30 min of ischemia. PGC1 α mRNA decrease is also inversely correlated to kidney dysfunction (p<0.001). A 10-minute ischemia led to the development of Chronic Kidney Disease (CKD), as evidenced by an incomplete recovery of the kidney function at 28 days. QPRT and PGC1 α mRNA expression showed a progressive but incomplete recovery during the transition from AKI to CKD compared to sham mice. Conclusions: In addition to confirming the decrease of PGC α and QPRT mRNA expression during AKI, we show that it is correlated to the severity of the ischemic AKI. Furthermore, we describe the recovery during renal repair and transition to CKD.

Knockdown of nicotinamide N-methyltransferase ameliorates renal fibrosis caused by ischemia–reperfusion injury and remodels sphingosine metabolism

The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia

The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease

Nicotinamide Mononucleotide Attenuates Renal Interstitial Fibrosis after AKI by Suppressing Tubular DNA Damage and Senescence

NMDA Receptor-mediated CaMKII/ERK Activation Contributes to Renal Fibrosis

Nicotinamide riboside: A promising therapy for MI-induced acute kidney injury by upregulating nicotinamide phosphoribosyltransferase-mediated NAD levels

Impaired Nicotinamide Adenine Dinucleotide Biosynthesis in the Kidney of Chronic Kidney Disease

Renal Fibrosis: SIRT1 Still of Value

Unraveling the nexus of NAD+ metabolism and diabetic kidney disease: insights from murine models and human data

Protective Effect of Nicotinamide Adenine Dinucleotide Phosphate on Renal Ischemia-Reperfusion Injury

Inorganic nitrate and nitrite ameliorate kidney fibrosis by restoring lipid metabolism via dual regulation of AMP-activated protein kinase and the AKT-PGC1α pathway

Nicotinamide mononucleotide ameliorates adriamycin-induced renal damage by epigenetically suppressing the NMN/NAD consumers mediated by Twist2

NAD+ precursor supplementation prevents mtRNA/RIG-I-dependent inflammation during kidney injury

NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury

Renal Mitochondria Exhibit Cell Type-Specific Heterogeneity and Are Functionally Dynamic

Reversing Acute Kidney Injury Through Coordinated Interplay of Anti‐inflammation and Iron Supplementation

Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease

Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome

Kirenol alleviates diabetic nephropathy via regulating TGF-β/Smads and the NF-κB signal pathway

Ultrasmall Polyphenol‐NAD+ Nanoparticle‐Mediated Renal Delivery for Mitochondrial Repair and Anti‐Inflammatory Treatment of AKI‐to‐CKD Progression